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1  | INTRODUC TION
A pandemic due to a novel coronavirus, named severe SARS-CoV-2, 
is ongoing. At the beginning of January, 2020, SARS-CoV-2 has 
been first identified as the cause of COVID-19 in China and it is now 
spreading worldwide.
The clinical manifestation of COVID-19 can vary from an asymp-
tomatic course to ARDS requiring invasive mechanical ventilation 
and extracorporeal membrane oxygenation.1 Patients at higher risk 
to develop a severe disease usually suffer from hypertension, car-
diovascular diseases, diabetes and malignancy. Roughly, 25% of hos-
pitalized patients need ICU admission, and mortality in this group is 
around 5%.2 Patients with solid organ transplant might be at higher 
risk to develop a severe disease and to have an unfavorable out-
come. However, data on these patients are lacking. We report here 
a case of a kidney-transplanted patient who received a diagnosis of 
infection due to SARS-CoV-2.
2  | C A SE REPORT
A 50-year-old man received a kidney transplant in 2016 (a previous 
kidney transplant was performed in 1993, but the organ was lost 
due to rejection in 2008) for IGA correlated nephropathy. He suf-
fered from hypertension, treated with amlodipine, and diabetes. His 
immunosuppressive regimen consisted of tacrolimus and mycophe-
nolate mofetil. On March 4, 2020 he started complaining fever and 
cough and he was admitted to the emergency room of another hos-
pital Hospital on March 8, 2020. His parameters on admission were 
a body temperature of 37.3°C, blood pressure 120/80 mm Hg, heart 
rate 64 bpm. An arterial blood gas analysis showed pH 7.38, pO2 
79 mm Hg, pCO2 31 mm Hg. Blood examination revealed a white 
blood cells count (WBC) of 3200 × 103/µL, Lymphocytes 600 × 103/
µL, lactate dehydrogenase 277 mU/mL. IL6 plasma level on March 
16, 2020 was 26.22 pg/mL (normal value 0-3.12). The patient was 
dismissed home the same day. Due to persistence of fever (around 
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The clinical manifestation of COVID-19 can vary from an asymptomatic course to 
ARDS requiring invasive mechanical ventilation and extracorporeal membrane oxy-
genation. A kidney transplanted patient infected with SARS CoV-2 infection showed 
a mild disease despite immune suppression. It is possible that Immunosuppression 
can “be protective” as the cytokine storm is an important factor in the disease story. 
Despite the good outcome reported in the present case report, is remains of vital 
importance the solid organ transplant patients use precautions in order to avoid the 
infection.
K E Y W O R D S
clinical research/practice, immunosuppressant – calcineurin inhibitor: tacrolimus, infection 
and infectious agents – viral, infectious disease
     |  1883SEMINARI Et Al.
37.5°C) and cough he was admitted to our hospital on March 13, 
2020. Nasopharyngeal swab was positive for SARS CoV-2 RT-PCR. 
Chests x-ray showed minimal interstitial lesions. Laboratory data are 
reported in Table 1. Since no respiratory symptoms were reported 
and drug interactions between lopinavir/ritonavir (LPV/r) and pa-
tients' daily medications were extensively detected, antivirals and 
hydroxychloroquine were not administrated. Immunosuppressive 
therapy was unchanged. Conversely, ceftriaxone was administrated 
as prophylactic antibiotic coverage. On March 17, 2020 he was dis-
charged home breathing in ambient air and without fever.
3  | DISCUSSION
Given to the extent of the SARS-CoV-2 pandemic, solid organ trans-
plant recipients are at risk to contract the disease. Nonetheless, dis-
ease course and prognosis in this group are unknown at the moment.
Although viral pneumonia in solid organ transplant patients may 
present with mild or atypical symptoms at onset, complications 
occur more frequently than in immunocompetent hosts.3
A previous study described the clinical characteristics of two kid-
ney-transplant recipients affected by MERS-CoV infection and re-
ported a variable outcome – death in one case and complete resolution 
in the other case.4 The first case was complicated by acute renal fail-
ure. Despite a T lymphocyte depletion due to antithymocyte globulin 
6 weeks before MERS Cov infection, the second patient had a favor-
able outcome. As the novel corona virus belongs to the Betacoronavirus 
family, which also contains SARS-CoV and MERS-CoV, it is possible the 
infections due to these different viruses share some similarities.
At the time of writing, a published report described two heart 
transplant recipients in China who presented with variable severity of 
disease (one mild and another with more severe manifestations requir-
ing a prolonged hospitalization). Both patients eventually survived.5
Lung viral infections can be associated with ARDS characterized 
by elevated levels of different cytokines, such as IL 2R, IL 6, and IL 
10.6 The pathogenesis of SARS-CoV-2 infection is as well associated 
with an immune over-reaction, resulting in a cytokines dysregulated 
release in particular in those patients who develop this condition.7
Patients needing ICU care have higher plasma levels of many 
innate cytokines, IP-10, MCP-1, MIP-1A, and TNFα. These clinical 
features suggest that involvement of highly pro-inflammatory con-
dition in the disease progression and severity is likely. In patients 
with a benign outcome, the symptoms are cleared by the fifth day 
from onset.2 The evolution of the disease in the patient described 
here was favorable, as he was discharged in good clinical conditions 
after 10 days from symptoms onset. In general 8 days is the main 
time window between onset of first symptoms and development of 
ARDS.2 The IL 6 plasma level at discharge was 26.22 pg/mL, a value 
below the median level observed in patients requiring high O2 flow.
8 
It can be hypothesized that solid organ transplant patients might be 
protected by immunosuppressive therapy that might dampen the 
cytokine storm, is an important factor in the disease story.
Despite the good outcome reported in the present case report, 
it is of vital importance for solid organ transplant patients to use 
precautions in order to avoid the infection.
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TA B L E  1   Laboratory parameters
 
March 8, 
2020
 March 
13, 2020
  March 17,  
2020
White blood cell (×103/µL) 3530 3200 2880
Neutrophils (×103/µL) 1850 2400 1590
Lymphocytes (×103/µL) 1210 600 890
Monocytes (×103/µL) 640 300 380
Eosinophils (×103/µL) 10 0 0
Creatinine (mg/dL) 1.7 1.65 1.37
C-reactive protein (mg/dL)  1.86  
LDH (mU/mL) 167 277  
ASL (mU/mL) 22   
ALT (mU/mL) 14  62
IL6 (pg/mL)   26.22a 
aPerformed on March 16, 2020. 
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